Work

Reduction in Immunoglobulin (IVIG or Anti D) Use in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving AMG 531: Results from Two Phase 3 Randomized Placebo-Controlled Trials.

Year: 2007

Type: article

Source: Blood

DOI: 10.1182/blood.v110.11.1304.1304

Authors: Vinod Pullarkat, Terry B. Gernsheimer, J. Th. M. de Wolf, Troy H. Guthrie, Adrian Newland, Jeffrey S. Wasser, Solomon I. Hamburg, Sue Gao, Ron Stewart, Janet L. Nichol

Institutions: City Of Hope National Medical Center, City of Hope, University of Washington, University Medical Center Groningen, Queen Mary University of London, Tower Cancer Research Foundation, Amgen (United States)

Language: English

Topic: Platelet Disorders and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2560309559

FWCI: 1.224

Cites:

Cited by: 6

Related to: 10